SCHEMBL20914252

SCHEMBL20914252

Cc1[nH]c2c(-c3ccccc3)c(C(F)(F)F)nn2c(=O)c1-c1nnc(C2CCCN(S(C)(=O)=O)C2)o1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.38
▸ PLAT P00750 3/20 0.36
▸ LMNA P02545 4/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ TP53 P04637 2/20 0.33
▸ POLB P06746 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ HDAC3 O15379 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ MAP3K12 Q12852 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914101 0.91 MAPT (0.40) PLATLMNASMN1; SMN2KMT2AMAPT
SCHEMBL20914007 0.89 PLAT (0.43) HSD11B1PLATMEN1GAAKMT2A
SCHEMBL20914105 0.88 PLAT (0.42) HSD11B1PLATGAAMAPTPOLB
SCHEMBL20914353 0.88 HSD11B1 (0.44) HSD11B1PLATMEN1KMT2APOLB
SCHEMBL20913972 0.85 PLAT (0.42) HSD11B1PLATPOLBTLR9TLR8
SCHEMBL20914350 0.84 PLAT (0.38) HSD11B1PLATMEN1GAAKMT2A
SCHEMBL20914301 0.84 PLAT (0.38) HSD11B1PLATMEN1GAAKMT2A
SCHEMBL20914368 0.84 PLAT (0.38) HSD11B1PLATMEN1GAAKMT2A
SCHEMBL20914226 0.84 PLAT (0.47) PLAT
SCHEMBL20914147 0.84 PLAT (0.38) PLATMEN1GAAKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 HSD11B1 3808/4885PLAT 1323/4885LMNA 4242/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 HSD11B1 3808/4885PLAT 1323/4885LMNA 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback